These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34919338)

  • 1. Impact of bacillus Calmette-Guerin intravesical therapy on the diagnostic efficacy of The Paris System for Reporting Urinary Cytology in patients with high-grade bladder cancer.
    Hermans J; Jokisch F; Volz Y; Eismann L; Pfitzinger P; Ebner B; Weinhold P; Schlenker B; Stief CG; Tritschler S; Schulz GB
    Cancer Cytopathol; 2022 Apr; 130(4):294-302. PubMed ID: 34919338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Paris system classification for urinary cytology in patients under bacillus Calmette-Guerin treatment.
    Moulavasilis N; Stravodimos K; Meletis E; Levis P; Leftheriotis V; Lazaris A; Constantinides C; Mikou P
    Diagn Cytopathol; 2022 Jun; 50(6):289-294. PubMed ID: 35262275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Pierconti F; Martini M; Fiorentino V; Cenci T; Capodimonti S; Straccia P; Sacco E; Pugliese D; Cindolo L; Larocca LM; Bassi PF
    Urol Oncol; 2021 Feb; 39(2):131.e17-131.e21. PubMed ID: 32773233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Implementation and Diagnostic Accuracy of the Paris Classification for Reporting Urinary Cytology in Voided Urine Specimens: A Cyto-Histological Correlation Study in a Cancer Center.
    Lobo J; Lobo C; Leça L; Rodrigues Â; Henrique R; Monteiro P
    Pathobiology; 2023; 90(4):233-240. PubMed ID: 36574757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
    Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
    Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma.
    Yamasaki M; Taoka R; Katakura K; Matsunaga T; Kani N; Honda T; Harada S; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Tsunemori H; Ueda N; Haba R; Sugimoto M
    BMC Urol; 2022 Apr; 22(1):51. PubMed ID: 35382830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the Paris system for reporting urinary cytology with histologic follow-up.
    Rohra P; Ocampo Gonzalez FA; Yan L; Mir F; Furlan K; Basu S; Barua A; Cheng L; Park JW
    Diagn Cytopathol; 2021 Jun; 49(6):691-699. PubMed ID: 33600080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intravesical instillation on performance of uCYT+ test.
    Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
    Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An institutional experience with The Paris System: A paradigm shift from ambiguous terminology to more objective criteria for reporting urine cytology.
    Roy M; Kaushal S; Jain D; Seth A; Iyer VK; Mathur SR
    Cytopathology; 2017 Dec; 28(6):509-515. PubMed ID: 28833848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should "suspicious for high-grade urothelial carcinoma" and "positive for high-grade urothelial carcinoma" remain separate categories?
    Nguyen L; Nilforoushan N; Krane JF; Bose S; Bakkar R
    Cancer Cytopathol; 2021 Feb; 129(2):156-163. PubMed ID: 33036060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
    Gupta M; Milbar N; Tema G; Pederzoli F; Chappidi M; Kates M; VandenBussche CJ; Bivalacqua TJ
    World J Urol; 2019 Oct; 37(10):2051-2058. PubMed ID: 30671639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy than the Paris System but the Paris System Is More Applicable for Suspicious Category.
    Celik B; Kavas G
    Acta Cytol; 2023; 67(4):425-433. PubMed ID: 36731438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
    Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal tuberculosis caused by intravesical instillation with Bacillus Calmette-Guérin (BCG) following nephroureterectomy in a patient with bladder and upper tract urothelial cancer: a case report.
    Allaeys C; De Backer P; Decaestecker K; Berquin C; Decaestecker K; Callens S; Van Praet C
    Acta Clin Belg; 2023 Jun; 78(3):257-260. PubMed ID: 35943041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria.
    Folarin OS; Siddiqui MT
    Cancer Cytopathol; 2023 Nov; 131(11):708-715. PubMed ID: 37572083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
    Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
    J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
    BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.